Tyme Technologies (TYME) Reports Q2 Loss of $0.03; Cash and Cash Equivalents of $96.6M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
November 8, 2021 6:50 AM ESTFirst patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor
PanCAN Precision Promise trial to add five new sites in early 2022
Commenced preclinical initiative with Evotec, a global leader in drug development, to evaluate the potential of expanding our SM-88 platform to other indications
Maintained a well-capitalized position, with $96.6 million in cash and marketable securities as of September 30
Company to host live conference... More
